Wellcome Trust Case Control Consortium to Use Illumina BeadChips to Study 90K Samples | GenomeWeb
NEW YORK (GenomeWeb News) – Scientists in the Wellcome Trust Case Control Consortium 2 will use Illumina’s Infinium HD BeadChips in a large-scale project to identify genetic variants linked to a number of diseases, including multiple sclerosis, schizophrenia, and asthma, the company said today.
 
Illumina said the Wellcome Trust-funded initiative, which comprises the WTCCC2 and 12 independent consortia, will analyze 90,000 DNA samples for both SNPs and copy number variants.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.